Indoco Remedies announced the receipt of GCP & GLP accreditation from the UK-MHRA (Medicines and Healthcare Products Regulatory Agency) for its clinical research organisation - AnaCipher, located at Hyderabad for the virtual inspection carried out from 4th - 7th May and 10th - 11th May 2021. The inspection covered all the phases of Bioequivalence studies and was conducted successfully.

"This is an exciting step in our journey of excellence and a validation of our adherence to delivering quality services to our customers worldwide.", stated Aditi Kare Panandikar, Managing Director, Indoco Remedies Limited.

AnaCipher CRO, based in Hyderabad, is a USFDA inspected clinical research facility and is spread over 30,000 sq. ft area with 98 beds and staffed by experienced professionals providing clinical trial solutions and conducts Bioequivalence and Bioavailability (BA/BE) studies at its facility. The CRO also has expertise in Bioanalytical work for new chemical entities (Phase I-III studies) for pharmaceutical companies globally. The CRO has successfully completed more than 500 studies in multiple therapeutic areas such as cardiovascular, diabetes, oncology, antiretrovirals and antacids.